 "Dr Reddy's rallies after receiving EIR from USFDA")
Dr Reddy’s Laboratories moved higher by 10% to Rs 2,494 on the BSE at 10:16 AM; after the company said its facility at Vishakhapatnam received Establishment Inspection Report (EIR) from the US health regulator, but the inspection has not closed.
The stock erased most of its gain and was trading 3% higher at Rs 2,498 on the BSE and NSE at 10:42 AM. The trading volumes on the counter more than doubled with a combined 1.07 million shares changed hands in first one-and-half hour of trading on both the exchanges.
Dr Reddy’s Laboratories said in a regulatory filing said that with regard to the US Food and Drug Administration (FDA) audit for the company’s formulations manufacturing facility, at Duvvada, Vishakhapatnam, Andhra Pradesh, the company received the EIR from the US FDA for the said facility.
However, in cover letter to the EIR, FDA has explained that the inspection has not closed, and the site’s status remains unchanged, but the FDA has released the EIR in order to be transparent about its regulatory process.
Dr Reddy’s planning to request a re-inspection in 2018 after further discussion on scheduling with FDA, it added.
On March 8, 2017, the company informed the stock exchanges that the USFDA had issued a Form 483 with 13 observations for the above mentioned facility.
The FDA issues a Form-483 if its investigators spot any conditions that in their judgment may constitute violations of the US Food Drug and Cosmetic (FD&C) Act and related laws.
The stock erased most of its gain and was trading 3% higher at Rs 2,498 on the BSE and NSE at 10:42 AM. The trading volumes on the counter more than doubled with a combined 1.07 million shares changed hands in first one-and-half hour of trading on both the exchanges.
Dr Reddy’s Laboratories said in a regulatory filing said that with regard to the US Food and Drug Administration (FDA) audit for the company’s formulations manufacturing facility, at Duvvada, Vishakhapatnam, Andhra Pradesh, the company received the EIR from the US FDA for the said facility.
However, in cover letter to the EIR, FDA has explained that the inspection has not closed, and the site’s status remains unchanged, but the FDA has released the EIR in order to be transparent about its regulatory process.
Dr Reddy’s planning to request a re-inspection in 2018 after further discussion on scheduling with FDA, it added.
On March 8, 2017, the company informed the stock exchanges that the USFDA had issued a Form 483 with 13 observations for the above mentioned facility.
The FDA issues a Form-483 if its investigators spot any conditions that in their judgment may constitute violations of the US Food Drug and Cosmetic (FD&C) Act and related laws.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%